$2.85 Billion is the total value of DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)'s 114 reported holdings in Q2 2018. The portfolio turnover from Q1 2018 to Q2 2018 was 39.6% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| MNKKQ | Sell | MALLINCKRODT PUB LTD CO | $130,401,000 | +4.5% | 6,988,248 | -18.9% | 4.58% | +5.9% |
| MYL | Sell | MYLAN N V | $62,960,000 | -40.0% | 1,742,111 | -31.6% | 2.21% | -39.2% |
| BOLD | Sell | AUDENTES THERAPEUTICS INC | $40,061,000 | -3.7% | 1,048,430 | -24.3% | 1.41% | -2.4% |
| ANAB | Sell | ANAPTYSBIO INC | $39,995,000 | -51.6% | 562,989 | -29.1% | 1.40% | -50.9% |
| CNC | Sell | CENTENE CORP DEL | $39,986,000 | -36.4% | 324,536 | -44.8% | 1.40% | -35.5% |
| Sell | TRINITY BIOTECH INVT LTDnote 4.000% 4/0 | $35,398,000 | -8.2% | 43,000,000 | -10.4% | 1.24% | -7.0% | |
| BCRX | Sell | BIOCRYST PHARMACEUTICALS | $34,744,000 | -1.1% | 6,063,496 | -17.7% | 1.22% | +0.2% |
| ECYT | Sell | ENDOCYTE INC | $32,075,000 | +34.3% | 2,324,299 | -11.5% | 1.13% | +36.2% |
| GKOS | Sell | GLAUKOS CORP | $30,652,000 | -39.5% | 754,222 | -54.1% | 1.08% | -38.7% |
| AGIO | Sell | AGIOS PHARMACEUTICALS INC | $29,481,000 | -1.5% | 350,000 | -4.4% | 1.04% | -0.2% |
| LCI | Sell | LANNET INC | $24,498,000 | -44.3% | 1,801,353 | -34.3% | 0.86% | -43.6% |
| NTRA | Sell | NATERA INC | $20,341,000 | -31.0% | 1,080,829 | -66.0% | 0.71% | -30.1% |
| AIMT | Sell | AIMMUNE THERAPEUTICS INC | $18,097,000 | -19.9% | 673,000 | -5.2% | 0.64% | -18.8% |
| ARNA | Sell | ARENA PHARMACEUTICALS INC | $17,361,000 | -37.0% | 398,194 | -42.9% | 0.61% | -36.1% |
| OXFD | Sell | OXFORD IMMUNOTEC GLOBAL PLC | $16,899,000 | -6.0% | 1,311,000 | -9.2% | 0.59% | -4.8% |
| CTMX | Sell | CYTOMX THERAPEUTICS INC | $16,687,000 | -22.1% | 729,948 | -3.1% | 0.59% | -21.1% |
| AVDL | Sell | AVADEL PHARMACEUTICALS PLCsponsored adr | $16,687,000 | -39.6% | 2,722,241 | -28.1% | 0.59% | -38.8% |
| BHVN | Sell | BIOHAVEN PHARMACTL HLDG CO L | $15,729,000 | -29.7% | 398,000 | -54.2% | 0.55% | -28.9% |
| DXCM | Sell | DEXCOM INC | $15,688,000 | -67.4% | 165,175 | -74.5% | 0.55% | -67.0% |
| GTHX | Sell | G1 THERAPEUTICS INC | $12,473,000 | -9.7% | 287,000 | -23.1% | 0.44% | -8.6% |
| WMGI | Sell | WRIGHT MED GROUP N V | $9,074,000 | -27.9% | 349,539 | -44.9% | 0.32% | -26.8% |
| RGNX | Sell | REGENXBIO INC | $8,969,000 | +17.2% | 125,000 | -51.2% | 0.32% | +18.9% |
| Sell | NUVASIVE INCnote 2.250% 3/1 | $7,591,000 | -31.0% | 7,000,000 | -30.0% | 0.27% | -29.9% | |
| WVE | Sell | WAVE LIFE SCIENCES LTD | $6,839,000 | -36.4% | 178,806 | -33.3% | 0.24% | -35.7% |
| BIOS | Sell | BIOSCRIP INC | $6,842,000 | -11.0% | 2,335,000 | -25.3% | 0.24% | -9.8% |
| PFNX | Sell | PFENEX INC | $6,112,000 | -38.6% | 1,129,684 | -31.9% | 0.22% | -37.7% |
| RCKT | Sell | ROCKET PHARMACEUTICALS INC | $5,496,000 | -26.7% | 280,000 | -30.0% | 0.19% | -25.8% |
| STDY | Sell | STEADYMED LTD | $4,132,000 | -10.4% | 918,120 | -35.3% | 0.14% | -9.4% |
| Sell | IGI LABORATORIES INCnote 3.750%12/1 | $3,476,000 | -67.7% | 3,733,000 | -67.8% | 0.12% | -67.2% | |
| MNKD | Sell | MANNKIND CORP | $2,771,000 | -18.0% | 1,458,537 | -1.6% | 0.10% | -17.1% |
| XNCR | Sell | XENCOR INC | $1,790,000 | -93.2% | 48,366 | -94.5% | 0.06% | -93.1% |
| NEOS | Sell | NEOS THERAPEUTICS INC | $1,458,000 | -79.7% | 233,332 | -73.0% | 0.05% | -79.5% |
| SCYX | Exit | SCYNEXIS INC | $0 | – | -1,020,000 | -100.0% | -0.05% | – |
| OBLN | Exit | OBALON THERAPEUTICS INC | $0 | – | -446,284 | -100.0% | -0.05% | – |
| EGLTQ | Exit | EGALET CORP | $0 | – | -3,239,237 | -100.0% | -0.07% | – |
| ADVM | Exit | ADVERUM BIOTECHNOLOGIES INC | $0 | – | -422,000 | -100.0% | -0.08% | – |
| TSRO | Exit | TESARO INC | $0 | – | -42,893 | -100.0% | -0.08% | – |
| IFRX | Exit | INFLARX NV | $0 | – | -88,500 | -100.0% | -0.09% | – |
| TCMD | Exit | TACTILE SYS TECHNOLOGY INC | $0 | – | -91,020 | -100.0% | -0.10% | – |
| ARMO | Exit | ARMO BIOSCIENCES INC | $0 | – | -188,525 | -100.0% | -0.24% | – |
| Exit | ALLSCRIPTS HEALTHCARE SOLUTNnote 1.250% 7/0 | $0 | – | -9,671,000 | -100.0% | -0.34% | – | |
| Exit | EXACT SCIENCES CORPdbcv 1.000% 1/1 | $0 | – | -12,500,000 | -100.0% | -0.38% | – | |
| REPH | Exit | RECRO PHARMA INC | $0 | – | -1,010,000 | -100.0% | -0.38% | – |
| PODD | Exit | INSULET CORP | $0 | – | -171,000 | -100.0% | -0.51% | – |
| MNLO | Exit | MENLO THERAPEUTICS INC | $0 | – | -426,749 | -100.0% | -0.56% | – |
| PTLA | Exit | PORTOLA PHARMACEUTICALS INCcall | $0 | – | -500,000 | -100.0% | -0.57% | – |
| PTLA | Exit | PORTOLA PHARMACEUTICALS INCput | $0 | – | -500,000 | -100.0% | -0.57% | – |
| MCK | Exit | MCKESSON CORP | $0 | – | -150,000 | -100.0% | -0.73% | – |
| CBIO | Exit | CATALYST BIOSCIENCES INC | $0 | – | -830,605 | -100.0% | -0.74% | – |
| GSK | Exit | GLAXOSMITHKLINE PLCsponsored adr | $0 | – | -810,000 | -100.0% | -1.10% | – |
| DVA | Exit | DAVITA INC | $0 | – | -486,427 | -100.0% | -1.11% | – |
| Exit | ISIS PHARMACEUTICALS INC DELnote 1.000%11/1 | $0 | – | -45,700,000 | -100.0% | -1.57% | – | |
| AVXS | Exit | AVEXIS INC | $0 | – | -755,798 | -100.0% | -3.24% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2018-08-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| AERIE PHARMACEUTICALS INC | 36 | Q3 2022 | 3.6% |
| CENTENE CORP DEL | 30 | Q3 2023 | 3.0% |
| BIOCRYST PHARMACEUTICALS INC | 29 | Q3 2023 | 2.2% |
| MOLINA HEALTHCARE INC | 26 | Q3 2022 | 1.7% |
| EHEALTH INC | 25 | Q3 2020 | 2.0% |
| INTERCEPT PHARMACEUTICALS IN | 24 | Q1 2023 | 2.2% |
| MYLAN NV | 23 | Q3 2020 | 6.2% |
| PORTOLA PHARMACEUTICALS INC | 23 | Q1 2019 | 6.0% |
| BROOKDALE SR LIVING INC | 23 | Q3 2023 | 2.2% |
| ALIMERA SCIENCES INC | 23 | Q3 2019 | 0.8% |
View DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)'s complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| DA32 Life Science Tech Acquisition Corp. | August 01, 2023 | 5,145,000 | 91.1% |
| CareMax, Inc. | March 13, 2023 | 18,691,423 | 16.4% |
| CareMax, Inc. | June 02, 2022 | 18,691,423 | 20.7% |
View DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)'s complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 3 | 2024-03-19 |
| 4 | 2024-03-19 |
| 4 | 2024-03-12 |
| 3 | 2024-03-08 |
| 4 | 2024-02-16 |
| 13F-HR | 2024-02-14 |
| 4 | 2024-02-08 |
| 3 | 2024-02-01 |
| 4 | 2023-11-21 |
| 13F-HR | 2023-11-14 |
View DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.